Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBT: 2020-2025

Historic EBT for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to -$6.6 million.

  • Biofrontera's EBT fell 17.24% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.5 million, marking a year-over-year decrease of 36.90%. This contributed to the annual value of -$17.7 million for FY2024, which is 11.83% up from last year.
  • Per Biofrontera's latest filing, its EBT stood at -$6.6 million for Q3 2025, which was down 25.27% from -$5.3 million recorded in Q2 2025.
  • Over the past 5 years, Biofrontera's EBT peaked at $5.6 million during Q1 2022, and registered a low of -$16.0 million during Q3 2021.
  • Its 3-year average for EBT is -$4.9 million, with a median of -$5.7 million in 2024.
  • In the last 5 years, Biofrontera's EBT soared by 258.25% in 2022 and then slumped by 2,137.55% in 2025.
  • Quarterly analysis of 5 years shows Biofrontera's EBT stood at -$14.5 million in 2021, then spiked by 80.80% to -$2.8 million in 2022, then spiked by 226.44% to $3.5 million in 2023, then slumped by 139.74% to -$1.4 million in 2024, then decreased by 17.24% to -$6.6 million in 2025.
  • Its EBT stands at -$6.6 million for Q3 2025, versus -$5.3 million for Q2 2025 and -$4.2 million for Q1 2025.